EU Panel Backs Apalutamide in Nonmetastatic CRPC

November 19, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) granted support for approval of apalutamide for the treatment of adult patients with nonmetastatic castration-resistant prostate cancer (CRPC) who are at high risk of developing metastatic disease, according to Janssen Pharmaceutical Companies, the developer of apalutamide, which announced the decision in a news release. “We are pleased with the CHMP’s … (leggi tutto)